/
•
•
Context is everything.
Detailed stories on technology startups, business and economic current affairs.
Detailed stories on technology startups, business and economic current affairs.
The Hyderabad-based generics maker is now India’s largest supplier of off-patent medicines to the US.
Editor's note: On 3 June, Aurobindo Pharma Ltd announced its annual results. It had turned in a stellar performance, with an all-round improvement in sales and profits. And, on 10 August, its stock raced past Rs 950, the highest level in a decade. But one highlight went almost unnoticed. In fiscal year 2020, the company’s US sales totted up to $1,622 million, making it the top pharmaceuticals supplier to the lucrative American market and ousting Sun Pharmaceutical Industries Ltd, which notched up $1,487 million, from the top slot. No small achievement this, considering Aurobindo Pharma’s ascension to the top of the exporters’ club makes it only the third company to grab the spot after Ranbaxy Laboratories Ltd, which held the position until it was merged with Sun Pharma in 2015. So why is this such a big deal? The US pharmaceutical market is also the world’s largest and consequently the biggest for generic drugs, medicines whose patents have expired and can be replicated. It was worth a whopping $115 billion in 2019, over five times the size of India's pharmaceutical industry as …
Quick-commerce apps are likely to run into regulations and poor order volumes as they try to grow this business.
The food and grocery delivery company’s idea of providing prescription drugs in 10 minutes is facing resistance from traditional pharma players.
Specialty drugs are fast becoming a lucrative market globally. And India’s largest drugmaker has done well to make the most of this opportunity so far. But it’s too soon to rest easy.
